Bluebird Bio, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Bluebird Bio's Q1 2025 results show increased product revenue but ongoing losses as the company navigates a pending merger and going concern uncertainties.
Bluebird Bio's Q3 2024 results show a net loss of $60.8 million, alongside a restructuring plan aimed at reducing operating expenses.
10-Q: Bluebird Bio Reports Second Quarter 2024 Results Amidst Restructuring and Financial Uncertainty
Bluebird Bio's Q2 2024 results show increased product revenue but significant net losses and concerns about its ability to continue as a going concern.
Bluebird Bio's first quarter 2024 results show a significant increase in product revenue to $18.6 million, driven by sales of ZYNTEGLO and SKYSONA.